STAT+: Lilly’s Ajax acquisition may have been worth it
Summary
This item discusses Eli Lilly’s Ajax acquisition in the context of broader biotech developments. It also notes a worsening Bicillin shortage that affected timely syphilis treatment during pregnancy. The piece mentions FDA approval of Sanofi’s diabetes drug Tzield after a contentious review. It also flags a proposed change from the Trump administration that could close a Medicare negotiation loophole.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected